PD-1, PD-L1, and BIM as Predictors of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.
作者信息
Kung Felix F, Arias-Mejias Suzette M, Quattrocchi Enrica, Sominidi-Damodaran Sindhuja, Bridges Alina G, Lehman Julia S, Weaver Amy L, Meves Alexander
机构信息
Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
J Invest Dermatol. 2020 Nov;140(11):2301-2304.e3. doi: 10.1016/j.jid.2020.03.948. Epub 2020 Apr 8.
Abstract
摘要
相似文献
1
PD-1, PD-L1, and BIM as Predictors of Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.程序性死亡受体1（PD-1）、程序性死亡配体1（PD-L1）和BIM作为原发性皮肤黑色素瘤前哨淋巴结转移的预测指标
J Invest Dermatol. 2020 Nov;140(11):2301-2304.e3. doi: 10.1016/j.jid.2020.03.948. Epub 2020 Apr 8.
2
Tumor PD-L1 expression, immune cell correlates and PD-1+ lymphocytes in sentinel lymph node melanoma metastases.前哨淋巴结黑色素瘤转移灶中的肿瘤PD-L1表达、免疫细胞相关性及PD-1+淋巴细胞
Mod Pathol. 2015 Dec;28(12):1535-44. doi: 10.1038/modpathol.2015.110. Epub 2015 Sep 25.
3
PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival.PD-1/PD-L1及VEGF-A/VEGF-C在淋巴结微环境中的表达及其与黑色素瘤转移和生存的关系
Melanoma Res. 2017 Dec;27(6):565-572. doi: 10.1097/CMR.0000000000000396.
4
Tumor associated PD-L1 expression pattern in microscopically tumor positive sentinel lymph nodes in patients with melanoma.黑色素瘤患者显微镜下肿瘤阳性前哨淋巴结中肿瘤相关PD-L1的表达模式
J Transl Med. 2015 Sep 30;13:319. doi: 10.1186/s12967-015-0678-7.
5
Probability of sentinel lymph node positivity in melanoma.黑色素瘤前哨淋巴结阳性的概率。
Eur J Cancer. 2019 Jul;116:10-12. doi: 10.1016/j.ejca.2019.04.034. Epub 2019 Jun 1.
6
Sentinel Lymph Nodes in Cutaneous Melanoma.皮肤黑色素瘤中的前哨淋巴结
Clin Lab Med. 2017 Sep;37(3):417-430. doi: 10.1016/j.cll.2017.05.002. Epub 2017 Jun 29.
7
Nodular primary cutaneous melanoma is associated with PD-L1 expression.结节性原发性皮肤黑色素瘤与 PD-L1 表达相关。
Eur J Dermatol. 2020 Aug 1;30(4):352-357. doi: 10.1684/ejd.2020.3846.
8
Soluble PD-L1 is a potential biomarker of cutaneous melanoma aggressiveness and metastasis in obstructive sleep apnoea patients.可溶性 PD-L1 是阻塞性睡眠呼吸暂停患者皮肤黑色素瘤侵袭性和转移的潜在生物标志物。
Eur Respir J. 2019 Jan 31;53(2). doi: 10.1183/13993003.01298-2018. Print 2019 Feb.
9
Correlation between ferromagnetic and isotopic tracers for sentinel lymph node detection in cutaneous melanoma: IMINEM study.黑色素瘤前哨淋巴结检测中磁性和同位素示踪剂的相关性：IMINEM 研究。
J Surg Oncol. 2021 Feb;123(2):654-659. doi: 10.1002/jso.26303. Epub 2020 Nov 25.
10
Lymphatic invasion predicts sentinel lymph node metastasis and adverse outcome in primary cutaneous melanoma.淋巴管浸润可预测原发性皮肤黑色素瘤前哨淋巴结转移及不良预后。
J Cutan Pathol. 2017 Sep;44(9):734-739. doi: 10.1111/cup.12969. Epub 2017 Jun 19.
本文引用的文献
1
Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.结合肿瘤分子和临床病理危险因素的模型可预测原发性皮肤黑色素瘤前哨淋巴结转移情况。
JCO Precis Oncol. 2020;4:319-334. doi: 10.1200/po.19.00206. Epub 2020 Apr 14.
2
The role of integrins in melanoma: a review.整合素在黑色素瘤中的作用：综述。
Int J Dermatol. 2020 May;59(5):525-534. doi: 10.1111/ijd.14850. Epub 2020 Mar 10.
3
Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.程序性死亡配体1的表达及黑色素瘤对抗程序性死亡1抗体帕博利珠单抗的反应
J Clin Oncol. 2016 Dec;34(34):4102-4109. doi: 10.1200/JCO.2016.67.2477. Epub 2016 Oct 31.
4
T cell Bim levels reflect responses to anti-PD-1 cancer therapy.T细胞Bim水平反映了对抗PD-1癌症治疗的反应。
JCI Insight. 2016 May 5;1(6). doi: 10.1172/jci.insight.86014.
5
Tumor Cell Adhesion As a Risk Factor for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma.肿瘤细胞黏附作为原发性皮肤黑色素瘤前哨淋巴结转移的危险因素
J Clin Oncol. 2015 Aug 10;33(23):2509-15. doi: 10.1200/JCO.2014.60.7002. Epub 2015 Jul 6.
6
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
7
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy.程序性死亡受体配体1（PD-L1）表达作为癌症免疫治疗中的预测生物标志物
Mol Cancer Ther. 2015 Apr;14(4):847-56. doi: 10.1158/1535-7163.MCT-14-0983. Epub 2015 Feb 18.
8
PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.黑色素瘤中PD-L1的表达在患者内部和患者之间表现出显著的异质性：对抗PD-1/PD-L1临床试验的启示。
Pigment Cell Melanoma Res. 2015 May;28(3):245-53. doi: 10.1111/pcmr.12340. Epub 2014 Dec 22.
9
Nivolumab in previously untreated melanoma without BRAF mutation.纳武利尤单抗治疗未经 BRAF 突变检测的初治黑色素瘤。
N Engl J Med. 2015 Jan 22;372(4):320-30. doi: 10.1056/NEJMoa1412082. Epub 2014 Nov 16.
10
Final trial report of sentinel-node biopsy versus nodal observation in melanoma.黑色素瘤前哨淋巴结活检与淋巴结观察的最终试验报告。
N Engl J Med. 2014 Feb 13;370(7):599-609. doi: 10.1056/NEJMoa1310460.
Zotero 插件